Day One Biopharmaceuticals, Inc. (DAWN) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 53.72M | 39.8M | 33.91M | 30.76M | 29.21M | 93.76M | 8.19M | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | 83.92% | -57.56% | 313.92% | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 6.08M | 4.48M | 3.77M | 2.88M | 2.98M | 1.59M | 707K | 116K | 103K | 99K | 92K | 89K |
| COGS % of Revenue | 11.32% | 11.26% | 11.1% | 9.38% | 10.21% | 1.7% | 8.63% | - | - | - | - | - |
| Gross Profit | 47.64M | 35.31M | 30.14M | 27.88M | 26.23M | 92.17M | 7.49M | -116K | -103K | -99K | -92K | -89K |
| Gross Margin % | 88.68% | 88.74% | 88.9% | 90.62% | 89.79% | 98.3% | 91.37% | - | - | - | - | - |
| Gross Profit Growth % | 81.64% | -61.69% | 302.71% | 24131.9% | 25562.14% | 93202.02% | 8235.87% | -30.34% | 42.78% | 40% | 30.83% | -1383.33% |
| Operating Expenses | 75.09M | 59.57M | 65.12M | 68.94M | 91.56M | 62.53M | 122.29M | 66.65M | 59.41M | 51.34M | 49.16M | 45.77M |
| OpEx % of Revenue | 139.79% | 149.68% | 192.04% | 224.13% | 313.47% | 66.7% | 1492.82% | - | - | - | - | - |
| Selling, General & Admin | 34.15M | 28.15M | 28.97M | 29.32M | 29.73M | 28.97M | 30.19M | 26.44M | 22.07M | 18.18M | 16.98M | 17.94M |
| SG&A % of Revenue | 63.57% | 70.73% | 85.43% | 95.33% | 101.8% | 30.9% | 368.48% | - | - | - | - | - |
| Research & Development | 40.95M | 31.42M | 36.15M | 39.62M | 61.82M | 33.56M | 92.11M | 40.21M | 37.35M | 33.16M | 32.18M | 27.83M |
| R&D % of Revenue | 76.23% | 78.95% | 106.61% | 128.8% | 211.66% | 35.8% | 1124.34% | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -27.46M | -24.25M | -34.97M | -41.07M | -65.33M | 29.64M | -114.81M | -66.77M | -59.52M | -51.44M | -49.25M | -45.85M |
| Operating Margin % | -51.12% | -60.94% | -103.14% | -133.5% | -223.68% | 31.61% | -1401.45% | - | - | - | - | - |
| Operating Income Growth % | 57.97% | -181.83% | 69.54% | 38.49% | -9.77% | 157.61% | -133.09% | -45.6% | -39.24% | -29.57% | -34.14% | -65.26% |
| EBITDA | -26.78M | -23.31M | -34.01M | -40.17M | -64.57M | 30.38M | -114.4M | -66.65M | -59.41M | -51.34M | -49.16M | -45.77M |
| EBITDA Margin % | -49.85% | -58.58% | -100.3% | -130.6% | -221.08% | 32.4% | -1396.47% | - | - | - | - | - |
| EBITDA Growth % | 58.53% | -176.73% | 70.27% | 39.73% | -8.68% | 159.18% | -132.7% | -45.63% | -39.59% | -29.86% | -34.37% | -65.25% |
| D&A (Non-Cash Add-back) | 679K | 939K | 964K | 894K | 759K | 746K | 408K | 116K | 103K | 99K | 92K | 89K |
| EBIT | -23.25M | -19.73M | -30.32M | -36M | -59.24M | 36.16M | -2.85M | -62.41M | -54.51M | -46.15M | -45.86M | -42.39M |
| Net Interest Income | 4.15M | 4.56M | 4.67M | 5.09M | 6.05M | 5.32M | 3.96M | 4.37M | 5.02M | 5.29M | 3.41M | 3.47M |
| Interest Income | 4.15M | 4.56M | 4.67M | 5.09M | 6.05M | 5.32M | 3.96M | 4.37M | 5.02M | 5.29M | 3.41M | 3.47M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 4.2M | 4.53M | 4.65M | 5.07M | 6.09M | 6.52M | 111.95M | 4.36M | 5.01M | 5.29M | 3.39M | 3.46M |
| Pretax Income | -23.25M | -19.73M | -30.32M | -36M | -59.24M | 36.16M | -2.85M | -62.41M | -54.51M | -46.15M | -45.86M | -42.39M |
| Pretax Margin % | -43.29% | -49.57% | -89.42% | -117.02% | -202.82% | 38.56% | -34.85% | - | - | - | - | - |
| Income Tax | -1.98M | 0 | 0 | 0 | 6.47M | -882K | 1.55M | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 8.5% | 0% | 0% | 0% | -10.93% | -2.44% | -54.36% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -21.28M | -19.73M | -30.32M | -36M | -65.71M | 37.04M | -4.41M | -62.41M | -54.51M | -46.15M | -45.86M | -42.39M |
| Net Margin % | -39.61% | -49.57% | -89.42% | -117.02% | -224.99% | 39.5% | -53.8% | - | - | - | - | - |
| Net Income Growth % | 67.62% | -153.26% | -588.04% | 42.33% | -20.55% | 180.25% | 90.39% | -47.22% | -35.91% | -22.11% | -25.55% | -52.78% |
| Net Income (Continuing) | -21.28M | -19.73M | -30.32M | -36M | -65.71M | 37.04M | -4.41M | -62.41M | -54.51M | -46.15M | -45.86M | -42.39M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.21 | -0.19 | -0.29 | -0.35 | -0.70 | 0.38 | -0.05 | -0.72 | -0.62 | -0.54 | -0.61 | -0.49 |
| EPS Growth % | 70% | -150% | -473.12% | 51.39% | -12.9% | 170.37% | 91.7% | -46.94% | -31.91% | -12.5% | -1.67% | -2.08% |
| EPS (Basic) | -0.21 | -0.19 | -0.29 | -0.35 | -0.70 | 0.38 | -0.05 | -0.72 | -0.62 | -0.54 | -0.61 | -0.49 |
| Diluted Shares Outstanding | 103.38M | 103.38M | 103.07M | 102.71M | 93.62M | 96.94M | 87.12M | 86.68M | 87.23M | 85.95M | 74.96M | 71.97M |
| Basic Shares Outstanding | 103.38M | 103.38M | 103.07M | 102.71M | 93.62M | 96.62M | 87.12M | 86.68M | 87.23M | 85.95M | 74.96M | 71.97M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |